Benzhydryl Compounds

• 

  Subject Areas on Research

  • A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A validated chiral HPLC method for the enantiomeric separation of tolterodine tartarate. 
  • Activation of metabotropic glutamate receptor 7 in spinal cord inhibits pain and hyperalgesia in a novel formalin model in sheep. 
  • An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. 
  • Analysis of bisphenol A diglycidyl ether (BADGE) and its hydrolytic metabolites in biological specimens by high-performance liquid chromatography and tandem mass spectrometry. 
  • Applications and societal benefits of plastics. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. 
  • Augmentation of dopaminergic agents for major depressive disorder. 
  • Biological assessment of bisphenol A degradation in water following direct photolysis and UV advanced oxidation. 
  • Biological assessments of a mixture of endocrine disruptors at environmentally relevant concentrations in water following UV/H2O2 oxidation. 
  • Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. 
  • Bisphenol A affects androgen receptor function via multiple mechanisms. 
  • Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoter. 
  • Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. 
  • Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. 
  • Comparison of fesoterodine and tolterodine in patients with overactive bladder. 
  • Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. 
  • Double-Blind, Placebo-Controlled, Crossover Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia. 
  • Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study. 
  • Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. 
  • Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. 
  • Elucidating the links between endocrine disruptors and neurodevelopment. 
  • Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. 
  • Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. 
  • Gene expression in oogenesis and implications for transgenerational effects of environmental toxicants. 
  • Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics. 
  • Investigation of maternal environmental exposures in association with self-reported preterm birth. 
  • Lower urinary tract symptoms revisited. 
  • Maternal serum bisphenol A levels and risk of pre-eclampsia: a nested case-control study. 
  • Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. 
  • Modafinil and cocaine interactions. 
  • Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. 
  • Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. 
  • Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. 
  • Muscarinic receptor antagonists in the treatment of overactive bladder. 
  • On chronic fatigue syndrome. 
  • Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. 
  • Palladium-catalyzed asymmetric diene cyclization/hydrosilylation employing functionalized silanes and disiloxanes. 
  • Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. 
  • Pediatric narcolepsy. 
  • Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. 
  • Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. 
  • Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. 
  • Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. 
  • Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. 
  • Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. 
  • Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA. 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • The selective metabotropic glutamate receptor 7 allosteric agonist AMN082 inhibits inflammatory pain-induced and incision-induced hypersensitivity in rat. 
  • Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. 
  • Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. 
  • Toxicology of environmental estrogens. 
  • Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. 
  • Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. 
  • Validation of the urinary sensation scale (USS). 
  • [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder]. 
• 

  Keywords of People

  • Gunn, Michael Dee, Professor of Medicine, Immunology
  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology